10:49 AM
 | 
Aug 08, 2018
 |  BC Extra  |  Financial News

Apexigen announces $73M in series B, C rounds

Immuno-oncology company Apexigen Inc. (San Carlos, Calif.) raised a total of $73 million in its series B and C rounds. The company closed its series B round with $15 million led by Decheng Capital, while the $58 million series C round was led by 3E Bioventures Capital, Virtus Inspire Ventures and SV Tech Ventures.

Apexigen's lead candidate APX005M is in Phase II testing to treat melanoma, non-small cell lung cancer (NSCLC), pancreatic cancer and renal cell carcinoma (RCC). The candidate is a humanized mAb that targets CD40.

Apexigen VP of Business Development Mark Nevins said the untranched funding will give the company more than two years of runway.

Decheng's Dan Zabrowski and 3E Bioventures' Karen Liu joined Apexigen's board.

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

Purchase this article for limited one-time distribution and website posting

$750 USD